Marcia Brose, MD
Medical Oncology · Philadelphia, PANPI 1316975451
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $183,747 of the $260,336 with a category attached, or 70.6%. 24 manufacturers reported payments, led by Bayer at 34.8% of the total. Reporting peaked in 2019 at $58,861 and has fallen 72.2% since, to $16,387 in 2025. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $1335.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$91K
- Eisai Inc.$65K
- Eli Lilly$34K
- Exelixis Inc.$28K
- Eisai CO., LTD.$27K
- Aadi Bioscience, Inc.$6K
- plus $9K from 18 others
Across 211 payments — averaging $16,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.9M
- Eisai Inc.$1M
- Novartis$209K
- Bayer$134K
- Blueprint Medicines Corporation$121K
- Exelixis Inc.$59K
- plus $43K from 4 others
What the payments were for
- Consulting fees$183,74771%
- Speaking & faculty fees$45,93018%
- Travel & lodging$26,08110%
- Food & beverage$4,5002%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 44 | $90,616 |
| Eisai Inc. | 39 | $64,803 |
| Eli Lilly | 10 | $34,270 |
| Exelixis Inc. | 42 | $28,407 |
| Eisai CO., LTD. | 8 | $27,301 |
| Aadi Bioscience, Inc. | 8 | $5,781 |
| Progenics Pharmaceuticals, Inc. | 7 | $3,527 |
| Blueprint Medicines Corporation | 1 | $2,240 |
| Lilly USA, LLC | 3 | $2,198 |
| Galvanize Therapeutics, Inc | 2 | $203 |
| E.r. Squibb & Sons, L.L.C. | 6 | $146 |
| Bristol Myers Squibb | 4 | $103 |
| Astellas Pharma US Inc | 2 | $102 |
| GSK | 1 | $100 |
| AstraZeneca | 1 | $100 |
| Caris MPI, Inc. | 1 | $99 |
| Gilead | 4 | $70 |
| Pfizer | 3 | $69 |
| Novartis | 3 | $53 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Sanofi | 1 | $36 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Array Biopharma Inc | 1 | $22 |
| Merck | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$85,008
- Vitrakvi$80,801
- Cabometyx$14,000
- Non-Covered$9,625
- FYARRO$5,670
- ALIYA SYSTEM$139
- TRELEGY ELLIPTA$100
How this compares
$260,336 in reported general payments places this provider in the 95th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 210 | $5,080,894 |
| CabometyxCabozantinib S-Malate | 49 | $1,840,983 |
| VitrakviLarotrectinib Sulfate | 12 | $470,161 |
| TafinlarDabrafenib Mesylate | 21 | $285,770 |
| CaprelsaVandetanib | 11 | $189,563 |
| SynthroidLevothyroxine Sodium | 60 | $5,471 |
| Levothyroxine Sodium | 138 | $2,789 |
| LoperamideLoperamide Hcl | 22 | $823 |
| Calcitriol | 13 | $324 |
| Amlodipine Besylate | 32 | $316 |
| Gabapentin | 19 | $193 |
| Oxycodone Hcl | 18 | $170 |
| Lisinopril | 14 | $144 |
| Citalopram HbrCitalopram Hydrobromide | 19 | $127 |
| Ibuprofen | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $64,803 | $5,080,894210 claims |
| Exelixis Inc.Cabometyx | $28,407 | $1,840,98349 claims |
| BayerVitrakvi | $90,616 | $470,16112 claims |
| NovartisTafinlar | $53 | $285,77021 claims |
| SanofiCaprelsa | $36 | $189,56311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
- Joshua BaumlPhiladelphia$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.